Tyrosine Kinase Domain Mutation Analysis
|Category||Specialist Integrated Haematological Malignancy Diagnostic Service (SIHMDS) >> Molecular Pathology|
Mutations in the tyrosine kinase domain of BCR-ABL are the most common cause of resistance to the tyrosine kinase inhibitors (TKI) in CML patients. Therefore, early detection of these mutations will guide clinicians to a more appropriate course of treatment. Sanger sequencing can detect a range of mutations within the TK domain to the level of approximately 20%
BCR-ABL1 positive patients that are relapsing or not responding to treatment.
|Sample & container required||20 mL peripheral blood or 3-5.0 mL bone marrow in EDTA (lavender top); 25uL of cDNA.|
|Transport storage||Samples must be less than 72 hours old upon receipt within the laboratory. Therefore, samples received after 3pm on a Friday will be rejected (unless they were taken on the same day).|
|Turnaround time||21 calendar days|